Sleep Soundly: The Global Market for Sleep Disorder Treatment

According to Helsestart data on global insomnia statistics for 2022 and 2023, half of US citizens experience insomnia at least once a month. In the Western world, around 59% of individuals suffer with insomnia at some point in their lives, making it the most vulnerable region in the globe. According to the same source, people in Japan, Taiwan, and Sweden suffer the most from insomnia than people in any other country on the planet. Norway had the most melatonin searches in the world, with 520 searches per 100,000 persons from 2021 to 2022, 67 more than Sweden.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-sleep-disorder-treatment-market

Data Bridge Market Research analyses that the Sleep Disorder Treatment Market which was USD 8,551.42 million in 2021, would rocket up to USD 16,914.58 million by 2029, and is expected to undergo a CAGR of 8.90% during the forecast period 2022 to 2029. An increase in general population knowledge of sleep problems is projected to boost the sleep disorders treatment industry. The growing number of people suffering from a variety of sleep disorders, including hallucinations, sleep paralysis, disrupted nocturnal sleep, insomnia, sleep apnea, narcolepsy, and circadian disorders, has piqued the interest of governments all over the world, compelling them to take action.

Growing level of stress is expected to drive the market's growth rate

Increased work-related stress adds to the rise of the insomnia market. Workload increases and demanding work schedules result in poor sleep quality. Furthermore, many people work unusual time shifts, such as security personnel, and the manufacturing industries run 24 hours a day, seven days a week. These irregular work shifts have an impact on the quality and cycle of sleep. Furthermore, the increase in the number of insomnia centers and sleep diagnostic centers contributes to the market's growth. Insomnia treatment centers help people improve their sleep quality, and sleep diagnostic centers serve as diagnostic laboratories for diagnosing sleep problems. Furthermore, the market is growing as more people choose non-pharmacological sleep therapy. Insomnia is frequently related with a person's mental state.

Report Scope and Market Segmentation

Segment Analysis:

The sleep disorder treatment market is segmented on the basis of type, treatment, route of administration, drugs type, population type, end user and distribution channel.

• On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep Apnea, restless legs syndrome (RLS), narcolepsy and others. Insomnia segment is dominating the market and is growing with the highest CAGR of 9.10% due to augmented pipeline products for the cure of the sleep disorders by major market players.
• On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others.

Pharmacological therapy segment of treatment segment is anticipated to dominate the sleep disorder treatment market

Pharmacological therapy segment is dominating the market and is growing with the highest CAGR of 10.00% because of the safe and economical form of administration leading to augmented uptake by the suffered patients.

• On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others. Oral segment is dominating the market and is growing with the highest CAGR of 9.10% because of the easy availability and economical nature of the generics drugs for the treatment of the sleep disorder.
• On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics.

Generics segment of drugs type segment is anticipated to dominate the sleep disorder treatment market

Generics segment is dominating the market and is growing with the highest CAGR of 9.30% due to the presence of the U.S. FDA approved pharmacological therapies for the cure of sleep disorder in adults

• On the basis of population type, the sleep disorder treatment market is segmented into children and adults. Adults segment is dominating the market and is growing with the highest CAGR of 9.10% because hospitals are the main location visited by patients for any surgery or procedure.
• On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. Hospitals segment is dominating the market and is growing with the highest CAGR of 9.20% because direct tender fulfils the requirement of patients and physicians.
• On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Direct tender segment is dominating the market and is growing with the highest CAGR of 9.5% because most of the facilities procure from direct tenders.

Major Players

Data Bridge Market Research recognizes the following companies as the major market players: Jazz Pharmaceuticals, Inc. (Ireland), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Arbor Pharmaceuticals Inc. (U.S.), Aurobindo Pharma USA (U.S.), Sanofi (U.S.),  Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC (U.S.), Lupin Pharmaceuticals, Inc. (India), Taj Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.), Mallinckrodt (U.K.), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceuticals Industries Ltd. (India), Taro Pharmaceutical Industries Ltd. (U.S.), DeVilbiss Healthcare LLC (U.S.), ResMed (U.S.).

Market Development

• In 2020, Jazz Pharmaceuticals plc announced in July that the FDA had approved its new medicine Xyway for the treatment of excessive daytime sleepiness and cataplexy in persons with narcolepsy over the age of 15 years. The FDA has authorised this novel treatment for sleep disorders. As a result, it has raised market demand and sales for its drug, resulting in greater revenue in the approaching period.
• In 2022, Idorsia commercially introduced Quviviq, an insomnia medicine, in May, with 500 sales agents and plans for a 'Robust' DTC campaign. Quviviq is a first-in-class, orexin receptor antagonist, which means it works by blocking the action of orexin, a neurotransmitter that is involved in wakefulness. The drug was approved by the US Food and Drug Administration (FDA) in January 2022 for the treatment of adults with insomnia who have difficulty falling asleep or staying asleep.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in the sleep disorder treatment market during the forecast period 2022-2029

North America is likely to dominate the market for sleep disorders for the foreseeable future, and this dominance is expected to last for a few more years. In addition, a solid clinical pipeline and rising stress levels are expected to drive revenue growth.

Asia-Pacific is estimated to be the fastest growing region in the sleep disorder treatment market in the forecast period 2022-2029

Asia-Pacific, on the other hand, is predicted to grow at a rapid pace during the forecast period. The market is expected to be driven by the rising prevalence of sleep disorders, increased awareness, rising demand for sleep disorder treatment, and high healthcare spending. Furthermore, favorable reimbursement rules for therapeutic products and rising disposable income are expected to drive revenue growth.

For more detailed information about the sleep disorder treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-sleep-disorder-treatment-market